

Embargoed: 0700hrs 15 March 2007

Akers Biosciences, Inc.

(“Akers Biosciences” or the “Company”)

Change of Director

Akers Biosciences which develops, manufactures, and supplies rapid, point of care screening and testing products, announces the appointment of Arthur W. Mullin as Chief Financial Officer of the Company.

Mr. Mullin’s appointment follows the decision by Paul B. Freedman to retire as a Director and Chief Financial Officer of the Company, a position he has held for 8 years. While Mr Freedman will step down from the Board with immediate effect, he will continue to remain involved with the Company for a period of approximately up to three months to facilitate the transition. The Board would like to thank Mr Freedman for his contribution to the Company’s development and to wish him well for the future.

Arthur W. Mullin has previously served as Chief Financial Officer of Kaiser Steel Corporation and of Kasser Industries, Inc., and as Executive Vice President of Royal Bank of Pennsylvania. His experience in the medical sector, as the former Chief Operating Officer of a division within United Healthcare, Inc, a US health plan provider serving more than 18 million Americans, will be particularly valuable as Akers Biosciences accelerates its sales and marketing programmes and enters its new phase as a significant product manufacturer.

It is expected that Mr. Mullin will be appointed as a director of the company at a future board meeting, and a further announcement will be made at that time.

Enquiries:

Dr. Ray Akers	Chief Executive Officer, Akers Biosciences, Inc.	001 856 848 8698
Thomas Nicolette	President, Akers Biosciences, Inc.	001 856 848 8698
Ben Simons	Hansard Group	020 7245 1100